Cargando…
The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma
Multiple myeloma (MM) treatment regimens have vastly improved since the introduction of immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies; however, MM is considered an incurable disease due to inevitable relapse and acquired drug resistance. Understanding the molecular mec...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Neoplasia Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166471/ https://www.ncbi.nlm.nih.gov/pubmed/35660848 http://dx.doi.org/10.1016/j.tranon.2022.101448 |